Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Eisai Co. Ltd
(OP:
ESALF
)
38.95
+1.42 (+3.78%)
Streaming Delayed Price
Updated: 3:52 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
925
Open
38.79
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
37.53
Today's Range
38.79 - 38.95
52wk Range
37.53 - 81.03
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab
March 22, 2024
Biogen and Eisai face delays as EMA postpones the oral explanation for the lecanemab review. Procedural issues at EMA prompt setback, impacting drug evaluation process amid recent EU court ruling.
Via
Benzinga
Merck, Eisai Report Yet Another Failure For Keytruda Plus Lenvima Combo Trial, This Time In Endometrial Cancer
December 08, 2023
Merck & Co Inc (NYSE: MRK) and Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) announced that the Phase 3 LEAP-001 trial of Keytruda (pembrolizu
Via
Benzinga
Performance
YTD
-21.52%
-21.52%
1 Month
-7.26%
-7.26%
3 Month
-16.15%
-16.15%
6 Month
-28.33%
-28.33%
1 Year
-31.67%
-31.67%
More News
Read More
Improved Alzheimer's Diagnosis Access: CMS Expands Amyloid PET Scan Usage
October 13, 2023
Via
Benzinga
LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly
October 10, 2023
Via
Benzinga
Amazon Invests $4B In ChatGPT Competitor, Hollywood Writers Accept Tentative Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories
September 25, 2023
Via
Benzinga
Current Analysis: Eisai Co Ltd (ESAIY)
July 16, 2023
Via
Talk Markets
Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi
September 25, 2023
Via
Benzinga
Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer
September 22, 2023
Via
Benzinga
Merck/Eisai's Cancer Combo Therapy Ambition Dashed Once Again, Companies Throw Towel On Head & Neck Trial
August 25, 2023
Via
Benzinga
Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts
July 07, 2023
Via
Benzinga
Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources
June 13, 2023
Via
Benzinga
Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote
June 12, 2023
Via
Benzinga
Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable'
June 08, 2023
Via
Benzinga
FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval
June 08, 2023
Via
Benzinga
Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen
May 04, 2023
Via
Benzinga
Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes!
April 21, 2023
Via
Benzinga
Merck, Eisai Shelve Keytruda Plus Lenvima Combo Trial In Skin Cancer Setting, Disappoints In Certain Type Of Colorectal Cancer
April 10, 2023
Via
Benzinga
National Institute on Aging Aims Building $300M Alzheimer's Research Database
April 03, 2023
Via
Benzinga
Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug
March 31, 2023
Via
Benzinga
Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments
March 16, 2023
Via
Benzinga
Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity
March 14, 2023
Via
Benzinga
Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment
March 06, 2023
Via
Benzinga
The 7 Best Growth Stocks to Buy for February 2023
February 06, 2023
Via
InvestorPlace
FDA Approves Biogen's Second Alzheimer's Treatment Under Accelerated Pathway
January 06, 2023
Via
Benzinga
Biogen's Alzheimer's Antibody Might Have A Third Death Associated With
December 22, 2022
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.